Celcuity’s (CELC) “Buy” Rating Reaffirmed at Needham & Company LLC

Posted by Geri Gentry on May 15th, 2026

Celcuity (NASDAQ:CELC – Get Free Report)‘s stock had its “buy” rating reissued by equities research analysts at Needham & Company LLC in a research report issued on Friday,Benzinga reports. They presently have a $157.00 target price on the stock. Needham & Company LLC’s price objective suggests a potential upside of 16.54% from the stock’s previous close.

A number of other research analysts also recently issued reports on the stock. Citizens Jmp boosted their price objective on shares of Celcuity from $150.00 to $160.00 and gave the company a “market outperform” rating in a research report on Monday, May 4th. Citigroup reissued an “outperform” rating on shares of Celcuity in a research note on Monday, May 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Celcuity in a report on Monday, April 20th. Wall Street Zen cut Celcuity from a “hold” rating to a “sell” rating in a research report on Saturday, April 25th. Finally, Craig Hallum reiterated a “buy” rating and set a $189.00 target price on shares of Celcuity in a report on Monday, May 4th. Ten analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $134.50.

Read Our Latest Stock Analysis on CELC

Celcuity Stock Performance

Celcuity stock opened at $134.72 on Friday. Celcuity has a 1-year low of $9.51 and a 1-year high of $151.02. The firm has a market cap of $6.51 billion, a P/E ratio of -35.55 and a beta of 0.09. The company has a current ratio of 10.55, a quick ratio of 10.55 and a debt-to-equity ratio of 3.20. The firm has a 50-day moving average of $118.35 and a 200-day moving average of $106.51.

Celcuity (NASDAQ:CELC – Get Free Report) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.97) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.10. Sell-side analysts expect that Celcuity will post -3.87 EPS for the current year.

Insider Transactions at Celcuity

In related news, Director Richard E. Buller sold 9,000 shares of the business’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $140.46, for a total transaction of $1,264,140.00. Following the sale, the director owned 6,760 shares of the company’s stock, valued at $949,509.60. The trade was a 57.11% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director David Dalvey sold 25,000 shares of the company’s stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $140.68, for a total transaction of $3,517,000.00. Following the completion of the sale, the director owned 65,000 shares in the company, valued at approximately $9,144,200. This trade represents a 27.78% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 37,000 shares of company stock worth $5,111,950 over the last ninety days. Insiders own 13.33% of the company’s stock.

Hedge Funds Weigh In On Celcuity

Several large investors have recently made changes to their positions in the business. Parallel Advisors LLC purchased a new stake in shares of Celcuity in the 1st quarter worth approximately $38,000. EverSource Wealth Advisors LLC boosted its holdings in Celcuity by 1,329.2% in the fourth quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company’s stock worth $34,000 after acquiring an additional 319 shares in the last quarter. Meeder Asset Management Inc. bought a new stake in Celcuity in the fourth quarter worth $42,000. PNC Financial Services Group Inc. grew its stake in shares of Celcuity by 20.1% in the first quarter. PNC Financial Services Group Inc. now owns 514 shares of the company’s stock worth $59,000 after acquiring an additional 86 shares during the last quarter. Finally, Ogorek Anthony Joseph NY ADV bought a new position in shares of Celcuity during the third quarter valued at $27,000. 63.33% of the stock is currently owned by hedge funds and other institutional investors.

About Celcuity

(Get Free Report)

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.